FDA Approves AstraZeneca’s Imfinzi Plus BCG for High-Risk Bladder Cancer
- nuaxia
- Jun 2
- 2 min read
The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care.
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC), becoming the first immunotherapy-based combination approved in this setting.
The decision was supported by Phase III POTOMAC trial data showing a 32% reduction in the risk of disease recurrence, progression, or death compared with BCG alone.
With more than five years of follow-up, the Imfinzi regimen delivered sustained disease-free survival benefits while maintaining a safety profile consistent with the individual therapies, reinforcing its potential to establish a new treatment benchmark for high-risk NMIBC patients.
Alert Type | Regulatory Approval (FDA) |
Drug/Device Name | Imfinzi (durvalumab) + Bacillus Calmette-Guérin (BCG) |
Indication | BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) in adults |
Therapy Area(s) | Oncology, Urology, Bladder Cancer, Immuno-oncology |
Geography | United States (FDA approval) |
What Changed | The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC. Based on the Phase III POTOMAC trial, the combination reduced the risk of high-risk disease recurrence, progression, or death by 32% compared with BCG alone, becoming the first approved immunotherapy combination in this setting. |
Clinical Relevance | The approval introduces a new treatment paradigm for high-risk NMIBC by adding immunotherapy to the long-established BCG backbone. The regimen demonstrated durable disease-free survival benefits over more than five years of follow-up while maintaining a manageable safety profile, preserving BCG treatment completion rates, and not negatively affecting patient-reported quality of life. |
Source Link | |
Date | 1-Jun-2026 |
Status | Draft |
Notes | POTOMAC Phase III data showed a disease-free survival hazard ratio of 0.68 with a median follow-up of 60.7 months. No new safety signals were identified versus the known profiles of Imfinzi and BCG. Regulatory reviews are ongoing in the EU, Japan, and other markets. The approval further expands Imfinzi’s role across the bladder cancer treatment pathway alongside ongoing Phase III programmes including VOLGA, NIAGARA, and NILE. |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments